The parameters of gas exchange markedly decreased in maize <i>zmstomagen1/2</i> mutant compared with in wild type (WT). by Juan-Juan Xu (18590868)

Mean ± SD values of unipedal stance parameters evaluated at the different time points of the postural training session. by Cristina Dolciotti (16317330)

Tetrandrine decreases Mtb antigen presentation. by Elham Karamooz (2584474)

<i>RTTN</i>-mutated organoids exhibit decreased proliferation and increased cell death at early stages. by Justine Guguin (9088672)

Exposure to high temperatures decreases the lifespan of <i>Strongyloides</i> spp. FLFs. by Ben T. Gregory (20442502)

Comparison of WEI values for two scenarios. by Danuta Roman-Liu (8532645)

Subjects:

Average stability values (mean ± standard deviation) and statistical results. by Hyung Suk Yang (20442438)

nsP4-C483Y or Q192L mutations decrease sensitivity to 4′-FlU. by Peiqi Yin (6533747)

PRCC values (with <i>p</i>-values in parentheses) for the median final population size and difference in mean MSI at the final time, without weevil predation and with weevil predat... by Alexandra M. Campbell (3284094)

Subjects:

Changes in work exposure as a function of relative time for seven fixed values of mean exposure. by Danuta Roman-Liu (8532645)

Subjects:

Depletion of most candidate CIA pathway proteins leads to a decrease in protein translation in <i>Toxoplasma gondii</i> parasites. by Evie R. Hodgson (21866946)

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

Knock-down of DYRK1A decreases HBV RNAs levels in HBV-infected dHepaRG cells. by Florentin Pastor (19852287)

MAP3K1, MAPK11, and PPP2R1A knockdown decreased ECM internalisation. by Montserrat Llanses Martinez (17797522)